Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis.

Rationale: The introduction of elexacaftor/tezacaftor/ivacaftor (ETI), a highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, to younger ages and the COVID-19 pandemic have significantly reduced pulmonary exacerbations requiring hospitalization among children with CF.

Objective: To assess demographic and clinical characteristics of children and young adults with CF hospitalized for pulmonary exacerbations before and after pediatric ETI approval.

Methods: A retrospective chart review was conducted at five United States CF Foundation-accredited care centers.